Asia Study Group of Prostate Cancer (A-CaP Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

20000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-03-31

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will target patients who have received a histopathological diagnosis of prostate cancer and who are undergoing treatment in various forms, including active PSA surveillance, surgical treatment, radiotherapy, endocrine therapy, and chemotherapy. The study will survey information about the patient at time of diagnosis, clinical staging, details of initial treatment, status of disease progression, and prognosis at the end point of the study. The purpose of the study is to clarify distribution of staging, the actual status of treatment choices and treatment outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Registry of Participants With Prostate Cancer in Asia

NCT02546908

Prostatic Neoplasms

COMPLETED

Protein Kinase A in Prostate Cancer Tissue.

NCT05460312

Prostate Neoplasm Inflammation Benign Hyperplasia of Prostate

UNKNOWN

Active Surveillance for Cancer of the Prostate (ASCaP)

NCT00949819

Prostate Cancer

RECRUITING

Extended Systematic Versus Mri-Assisted pRostate Transperineal Biopsy

NCT04685928

Prostate Cancer

COMPLETED NA

68Ga-XACP3 PET/CT in Prostate Cancer

NCT07242014

Prostate Cancer PET/CT ACP3

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The A-CaP will collect information in a linkable anonymized format from all medical institutions in Asian countries participating in the study and will engage in data analysis. J-CaP which has previous experience of engaging in a similar study in 2010 wll be a sponsor for A-CaP study, the aggregated results of which have been reported. The registration period for this study will be three years followed by 7 years of follow-up study, and research will be implemented across a wider range of Asian countries, with new institutions participating for the purposes of this study. As this study will be an observational study the acquisition of data will be relatively simple, and as the content of the study will be almost identical to the study conducted by J-CaP in 2010, a system for research implementation is already established at J-CaP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prostate Cancer

About 20,000 patients who have received a histopathological diagnosis of prostate cancer from ten countries in Asia.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who have received a histopathological diagnosis of prostate cancer between January 1,2016,and December 31,2018.
* Patients who, having received a diagnosis within the abovementioned period, began initial treatment for prostate cancer(including active surveillance).
* Patients who are either hospitalized as outpatients.